UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Ju ...

Continued Strong Results in Q2 FY 24 5 Q2 FY 24 Sales Drivers 50 PACK ORIGINAL Dual Action: Second Quarter FY 2024 Results November 2吋, 2023 I. Performance Update S E C O N D Q U A R T E R F Y 2 4 R E S U L T S eve ◼ Solid quarterly Revenue of $286.3 million, similar to prior year's record level ◼ Consumers continue to seek the benefits of trusted consumer healthcare brands ◼ Continue to benefit from leading & diversified portfolio ◼ Gross Margin as expected with sequential improvement ◼ Solid financial pro ...

[PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including income, balance sheets, and cash flows, with detailed notes on accounting policies and financial data [Condensed Consolidated Statements of Income and Comprehensive Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Income) Total revenues slightly decreased to $286.3 million for the three months, while net income increased to $53.6 million Condensed Consolidated Statements of Income and Comprehensive Income (in thousands, except EPS) | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Six Months Ended Sep 30, 2023 | Six Months Ended Sep 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | **Total Revenues** | $286,316 | $289,273 | $565,625 | $566,332 | | **Gross Profit** | $160,020 | $161,009 | $314,693 | $321,128 | | **Operating Income** | $88,250 | $84,384 | $173,444 | $171,398 | | **Net Income** | $53,559 | $51,023 | $106,835 | $106,295 | | **Diluted EPS** | $1.07 | $1.02 | $2.13 | $2.11 | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets slightly decreased to $3.33 billion, primarily due to a reduction in long-term debt to $1.26 billion Condensed Consolidated Balance Sheets (in thousands) | Balance Sheet Item | September 30, 2023 | March 31, 2023 | | :--- | :--- | :--- | | **Total Assets** | $3,332,874 | $3,353,729 | | Cash and cash equivalents | $60,067 | $58,489 | | Goodwill | $526,860 | $527,553 | | Intangible assets, net | $2,328,250 | $2,341,893 | | **Total Liabilities** | $1,796,915 | $1,906,645 | | Long-term debt, net | $1,262,972 | $1,345,788 | | **Total Stockholders' Equity** | $1,535,959 | $1,447,084 | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operations decreased to $110.5 million, while financing activities used $107.7 million for debt repayment and stock repurchases Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity | Six Months Ended Sep 30, 2023 | Six Months Ended Sep 30, 2022 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $110,547 | $115,787 | | **Net cash provided by (used in) investing activities** | $(611) | $(3,423) | | **Net cash used in financing activities** | $(107,728) | $(95,330) | | Increase (decrease) in cash and cash equivalents | $1,578 | $15,257 | - Key financing activities for the six months ended September 30, 2023 included **$85.0 million** in term loan repayments and **$25.0 million** for the repurchase of common stock[22](index=22&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail accounting policies, debt rate transition, stable goodwill, segment revenues, and significant customer concentration with Walmart and Amazon - The company's debt facilities transitioned their reference rate from LIBOR to the **Secured Overnight Financing Rate (SOFR)** effective July 1, 2023[31](index=31&type=chunk)[45](index=45&type=chunk) - As of September 30, 2023, the company determined no events occurred that would indicate potential impairment of its **$526.9 million** in goodwill or **$2.3 billion** in intangible assets[35](index=35&type=chunk)[38](index=38&type=chunk) - For the six months ended September 30, 2023, **Walmart** accounted for approximately **20.0%** of gross revenues and **Amazon** accounted for **10.3%**[68](index=68&type=chunk) Segment Revenues (Six Months Ended Sep 30, 2023, in thousands) | Segment Revenues | Revenue (in thousands) | | :--- | :--- | | **North American OTC Healthcare** | $490,566 | | **International OTC Healthcare** | $75,059 | | **Total Consolidated** | $565,625 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, noting slight revenue decreases, segment variations, gross profit margin changes, and cash flow utilization for debt reduction [Results of Operations (Three Months Ended Sep 30, 2023 vs 2022)](index=26&type=section&id=Results%20of%20Operations%20(Three%20Months)) Total revenues decreased 1.0% to $286.3 million, with North American OTC down 3.0% and International OTC up 12.6% Segment Revenue (Three Months Ended Sep 30, in thousands) | Segment Revenue | 2023 (in thousands) | 2022 (in thousands) | % Change | | :--- | :--- | :--- | :--- | | **North American OTC Healthcare** | $244,423 | $252,054 | (3.0)% | | **International OTC Healthcare** | $41,893 | $37,219 | 12.6% | | **Total Consolidated** | $286,316 | $289,273 | (1.0)% | - The North American revenue decline was primarily due to lower sales in **Women's Health**, **Analgesics**, and **Gastrointestinal** categories[88](index=88&type=chunk)[89](index=89&type=chunk) - The International revenue increase was driven by growth in **Eye & Ear Care** (+50.5%) and **Women's Health** (+49.0%)[88](index=88&type=chunk)[90](index=90&type=chunk) - Consolidated contribution margin increased by **2.3%** to **$119.9 million**, with the margin rate improving to **41.9%** from **40.5%** year-over-year, mainly due to reduced advertising and marketing spend in North America[96](index=96&type=chunk)[97](index=97&type=chunk) [Results of Operations (Six Months Ended Sep 30, 2023 vs 2022)](index=29&type=section&id=Results%20of%20Operations%20(Six%20Months)) Total revenues for the six-month period were nearly flat at $565.6 million, with North American OTC down 0.8% and International OTC up 4.6% Segment Revenue (Six Months Ended Sep 30, in thousands) | Segment Revenue | 2023 (in thousands) | 2022 (in thousands) | % Change | | :--- | :--- | :--- | :--- | | **North American OTC Healthcare** | $490,566 | $494,572 | (0.8)% | | **International OTC Healthcare** | $75,059 | $71,760 | 4.6% | | **Total Consolidated** | $565,625 | $566,332 | (0.1)% | - Gross profit margin for the six-month period decreased from **56.7%** to **55.6%** year-over-year, primarily due to increased supply chain costs and product mix, partly offset by pricing actions[108](index=108&type=chunk) - Net interest expense increased to **$35.3 million** from **$32.3 million**, as the average cost of borrowing rose to **5.4%** from **4.3%**, despite a decrease in average indebtedness[117](index=117&type=chunk) [Liquidity and Capital Resources](index=31&type=section&id=Liquidity%20and%20Capital%20Resources) Operating cash flow was $110.5 million, with $60.1 million cash and $171.2 million available credit, and total debt reduced to $1.3 billion - Net cash from operations was **$110.5 million** for the six months ended September 30, 2023, a decrease of **$5.2 million** from the prior year, primarily due to increased working capital[120](index=120&type=chunk)[121](index=121&type=chunk) - As of September 30, 2023, total outstanding indebtedness was **$1.3 billion**, and the company had a borrowing capacity of **$171.2 million** on its revolving credit facility[124](index=124&type=chunk) - The company is in compliance with its debt covenants, which include a leverage ratio of less than **6.50 to 1.0** and an interest coverage ratio greater than **2.25 to 1.0**[129](index=129&type=chunk)[130](index=130&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks from interest rate fluctuations on $275 million variable debt and foreign currency exposure, impacting pre-tax earnings - The company has **$275.0 million** of variable-rate debt; a **1.0%** increase in interest rates would reduce pre-tax earnings by approximately **$1.6 million** over a six-month period[138](index=138&type=chunk)[139](index=139&type=chunk) - A hypothetical **10.0%** adverse change in foreign currency exchange rates would impact pre-tax income by approximately **$4.1 million** for the six months ended September 30, 2023[141](index=141&type=chunk) [Controls and Procedures](index=36&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of September 30, 2023, with no material changes to internal controls - The Chief Executive Officer and Chief Financial Officer concluded that as of September 30, 2023, the Company's disclosure controls and procedures were **effective**[142](index=142&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that materially affected, or are reasonably likely to materially affect, internal controls[143](index=143&type=chunk) [PART II. OTHER INFORMATION](index=36&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors previously disclosed in the Annual Report on Form 10-K for the fiscal year ended March 31, 2023 - There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the fiscal year ended March 31, 2023[144](index=144&type=chunk) [Other Information](index=38&type=section&id=Item%205.%20Other%20Information) A company officer adopted a Rule 10b5-1 trading plan on September 15, 2023, to sell up to 15,871 shares - On September 15, 2023, Mary Beth Fritz, Senior Vice President, Quality & Regulatory Affairs, adopted a Rule 10b5-1 trading plan to sell a total of **15,871** ordinary shares; the plan expires on September 27, 2024[148](index=148&type=chunk) [Exhibits](index=39&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including officer certifications and Inline XBRL documents - The report includes standard exhibits such as officer certifications (**31.1, 31.2, 32.1, 32.2**) and XBRL data files (**101 series**)[150](index=150&type=chunk)

Financial Data and Key Metrics Changes - Q1 revenue of $279.3 million increased by 1.8% organically compared to the prior year, with EBITDA and EPS both slightly declining from the previous year, but EBITDA margin remained consistent with long-term expectations [2][3][12] - Total company gross margin was 55.4% in Q1, which increased sequentially but declined by 240 basis points year-over-year due to cost increases, partially offset by pricing actions and cost savings [5][7] - Diluted EPS for Q1 was $1.06, down from $1.09 in the prior year, impacted by cost increases and higher interest rates [7] Business Line Data and Key Metrics Changes - North America segment revenues increased by 1.8% and International segment revenues increased by 1.6% year-over-year, excluding foreign exchange effects [3] - The largest growth drivers in Q1 were gastrointestinal (GI) and skin care categories, with notable performance from Dramamine [4][42] Market Data and Key Metrics Changes - The international business, excluding FX, was up slightly as anticipated, with an outlook for mid-single-digit growth for the full year [18] - E-commerce channel continued to show year-over-year growth, reflecting a long-term trend of higher online purchasing [4] Company Strategy and Development Direction - The company reaffirmed its full-year outlook, anticipating revenue of $1.135 billion to $1.140 billion and organic revenue growth of approximately 1% to 2% versus fiscal '23 [12] - The company plans to continue investing in brand-building and maintaining a disciplined capital deployment strategy, focusing on reducing debt and building M&A capacity [75][78] Management's Comments on Operating Environment and Future Outlook - Management noted that inflation is largely wage-related and expected to remain consistent, with some relief on certain costs such as freight [16] - The company expects gross margin to remain consistent throughout the year, with Q2 estimated to be similar to Q1 [5][81] Other Important Information - The company generated $46.6 million in free cash flow in Q1, down from the prior year due to timing of working capital [8] - Approximately 425,000 shares were repurchased for $25 million, completing the previously authorized share repurchase program [9] Q&A Session Summary Question: Dynamic between units and pricing and cost normalization - Management indicated that for fiscal '24, they expect about 1 point of growth from price and 1 point from volume, with Q1 growth primarily from pricing [15][16] Question: Performance of Hydralyte in international business - Management stated that the international business, excluding FX, was up slightly as anticipated, with a return to historic growth levels expected [18] Question: Inventory levels at retail - Management noted that inventory levels have been consistent over the last few quarters, with no significant areas for restocking [19] Question: Women's health category outlook - Management anticipates stabilization and long-term growth for the women's health business, despite a year-over-year decline in the quarter [23][24] Question: Cough and cold category performance - Management expects more normalized trends in cough and cold sales, with inventory levels being filled at the retailer level [25][26] Question: Channel shifts and potential risks - Management observed some movement in shopper preferences but noted that they are well-positioned across all channels [27][29] Question: Advertising and marketing focus - Management confirmed that advertising and marketing resources are allocated based on opportunities and new product launches, with no significant changes in strategy [51][83]

RIPLE CLEAN O Safe Harbor Disclosure F I R S T Q U A R T E R F Y 2 4 R E S U L T S I. Performance Update F I R S T Q U A R T E R F Y 2 4 R E S U L T S Business Momentum Continued in First Quarter FY 24 ◼ Continued strong performance enabled by benefits of leading & diversified portfolio 50 rac Prestige Consumer HEALTHCARE ULTIMATE All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule or in our August 3, 2023 earnings releas ...

[PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) Presents unaudited condensed consolidated financial statements for Q2 2023, showing slight net income decrease and debt reduction [Condensed Consolidated Statements of Income and Comprehensive Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Income) Revenues slightly increased to $279.3M, but net income declined to $53.3M due to higher cost of sales | Financial Metric | Three Months Ended June 30, 2023 (in millions) | Three Months Ended June 30, 2022 (in millions) | | :--- | :--- | :--- | | **Total Revenues** | $279.3 | $277.1 | | **Gross Profit** | $154.7 | $160.1 | | **Operating Income** | $85.2 | $87.0 | | **Net Income** | $53.3 | $55.3 | | **Diluted EPS** | $1.06 | $1.09 | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets slightly decreased to $3.35B, long-term debt reduced to $1.32B, and equity rose to $1.48B | Balance Sheet Item | June 30, 2023 (in millions) | March 31, 2023 (in millions) | | :--- | :--- | :--- | | **Total Current Assets** | $391.8 | $391.7 | | **Total Assets** | $3,345.6 | $3,353.7 | | **Long-term debt, net** | $1,316.7 | $1,345.8 | | **Total Liabilities** | $1,865.3 | $1,906.6 | | **Total Stockholders' Equity** | $1,480.3 | $1,447.1 | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow decreased to $48.1M, with $54.2M used in financing for debt repayment and share repurchases | Cash Flow Activity | Three Months Ended June 30, 2023 (in millions) | Three Months Ended June 30, 2022 (in millions) | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $48.1 | $58.2 | | **Net cash provided by (used in) investing activities** | $2.3 | $(1.0) | | **Net cash used in financing activities** | $(54.2) | $(47.4) | | **Net change in cash and cash equivalents** | $(3.9) | $8.7 | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Details accounting policies, segment performance, debt, and customer concentration, noting economic uncertainties and major customer revenue - The company faces economic uncertainty from supply chain constraints, rising interest rates, and inflation, which could affect product demand, prices, and supply. To date, these conditions have not had a material negative impact on operations or liquidity[23](index=23&type=chunk)[24](index=24&type=chunk) - Significant revenue concentration exists with top customers. For the three months ended June 30, 2023, Walmart accounted for approximately **20.8%** of gross revenues, and Amazon accounted for **11.0%**[63](index=63&type=chunk) Segment Performance (Q1 FY2024) | Segment Performance (Q1 FY2024) | North American OTC | International OTC | Consolidated | | :--- | :--- | :--- | :--- | | **Total Revenues** | $246.1M | $33.2M | $279.3M | | **Contribution Margin** | $104.7M | $13.8M | $118.4M | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 FY2024 results, noting revenue growth, gross margin contraction, and liquidity for debt and share repurchases [Results of Operations](index=24&type=section&id=Results%20of%20Operations) Total revenues increased 0.8% to $279.3M, but gross profit fell 3.4% to $154.7M due to higher supply chain costs Revenue by Segment (Q1 FY2024 vs Q1 FY2023) | Revenue by Segment (Q1 FY2024 vs Q1 FY2023) | 2023 | 2022 | % Change | | :--- | :--- | :--- | :--- | | **North American OTC Healthcare** | $246.1M | $242.5M | +1.5% | | **International OTC Healthcare** | $33.2M | $34.5M | -4.0% | | **Total Consolidated** | $279.3M | $277.1M | +0.8% | - Gross profit margin decreased to **55.4%** from **57.8%** in the prior year, primarily due to increased supply chain costs and unfavorable product mix[85](index=85&type=chunk) - Interest expense increased to **$17.7 million** from **$15.3 million** YoY, as the average cost of borrowing rose to **5.3%** from **4.1%**, despite a decrease in average indebtedness[94](index=94&type=chunk) [Liquidity and Capital Resources](index=26&type=section&id=Liquidity%20and%20Capital%20Resources) Operating cash flow decreased to $48.1M, used for $30M debt repayment and $25M share repurchases, with $1.3B total debt Cash Flow Summary (Q1 FY2024 vs Q1 FY2023) | Cash Flow Summary (Q1 FY2024 vs Q1 FY2023) | 2023 | 2022 | | :--- | :--- | :--- | | **Cash from Operating Activities** | $48.1M | $58.2M | | **Cash from Investing Activities** | $2.3M | $(1.0)M | | **Cash used in Financing Activities** | $(54.2)M | $(47.4)M | | **Net Change in Cash** | $(3.9)M | $8.7M | - As of June 30, 2023, total outstanding indebtedness was **$1.3 billion**, consisting of senior notes and term loans. The company had no outstanding balance on its **$174.9 million** ABL Revolver[101](index=101&type=chunk)[105](index=105&type=chunk) - The company was in compliance with all financial covenants, including leverage ratio, interest coverage ratio, and fixed charge ratio requirements[105](index=105&type=chunk)[106](index=106&type=chunk)[107](index=107&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces interest rate risk on $330M variable-rate debt and foreign currency risk on 10.6% of revenues - The company has **$330.0 million** of variable-rate debt. A hypothetical **1.0%** increase in interest rates would adversely impact pre-tax earnings by approximately **$0.9 million** for the quarter[116](index=116&type=chunk)[117](index=117&type=chunk) - Approximately **10.6%** of gross revenues were denominated in foreign currencies. A hypothetical **10.0%** adverse change in foreign currency exchange rates would impact pre-tax income by approximately **$1.7 million** for the quarter[118](index=118&type=chunk)[119](index=119&type=chunk) [Item 4. Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of June 30, 2023, with no material changes to internal controls - Based on an evaluation as of June 30, 2023, the CEO and CFO concluded that the company's disclosure controls and procedures were effective[120](index=120&type=chunk) - No changes occurred during the quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[121](index=121&type=chunk) [PART II. OTHER INFORMATION](index=31&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1A. Risk Factors](index=31&type=section&id=Item%201A.%20Risk%20Factors) No material changes to previously disclosed risk factors from the Annual Report on Form 10-K for FY2023 - The risk factors described in the Annual Report on Form 10-K for the year ended March 31, 2023, have not materially changed during the period covered by this quarterly report[122](index=122&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=33&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company repurchased 515,432 shares, completing a $25M program and satisfying tax withholding obligations Share Repurchase Summary | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | **May 2023** | 363,138 | $59.88 | | **June 2023** | 152,294 | $57.54 | | **Total** | 515,432 | $59.19 | - The company completed its **$25.0 million** share repurchase program announced in May 2023 by repurchasing **426,479** shares[126](index=126&type=chunk) [Item 5. Other Information](index=33&type=section&id=Item%205.%20Other%20Information) Details 2023 Annual Meeting voting results, including director elections, auditor ratification, and executive compensation approval - At the Annual Meeting on August 1, 2023, all seven director nominees were elected to the Board[127](index=127&type=chunk) - Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024[128](index=128&type=chunk) - A non-binding resolution to approve named executive officer compensation was passed, and stockholders advised for future advisory votes on compensation to be held every one year[129](index=129&type=chunk)[130](index=130&type=chunk) [Item 6. Exhibits](index=35&type=section&id=Item%206.%20Exhibits) Lists all exhibits filed with Form 10-Q, including Term Loan Credit Agreement amendment and officer certifications - Key exhibits filed include Amendment No. 7 to the Term Loan Credit Agreement and officer certifications pursuant to SEC rules[132](index=132&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO ______ Commission File Number: 001-32433 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Inco ...

Financial Data and Key Metrics Changes - Q3 2023 revenues were $276 million, representing a 2% organic growth compared to the prior year, driven by strong performance in the cough and cold category and international segment [54][59] - Diluted EPS for Q3 was $1.4, with a year-to-date diluted EPS of $3.14, slightly down from $3.15 in the prior year due to gross margin compression [60][69] - Gross margin for the first nine months was 56%, a decline of 170 basis points from the previous year's adjusted gross margin of 57.7% [89][135] Business Line Data and Key Metrics Changes - The cough and cold category saw over 20% growth year-to-date, while the women's health and eye & ear care categories experienced declines [70][88] - International segment revenues increased by over 25% in Q3, excluding foreign exchange effects, with strong performance across various regions and product categories [73] Market Data and Key Metrics Changes - North American revenues were down approximately 1% year-over-year, with significant increases in cough and cold and gastrointestinal categories offset by declines in women's health and eye & ear care [88] - E-commerce now accounts for about 15% of total sales, continuing to grow in the high single digits [103] Company Strategy and Development Direction - The company aims to maintain a consistent pipeline of new products and innovation, with expectations for continued growth in fiscal 2024 [107] - Strategic investments in inventory are being made to better align with retail customer service requirements and to mitigate supply chain disruptions [29][70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's positioning and consumption trends, anticipating continued growth in fiscal 2024 after two record years [16][68] - The company is adapting to a dynamic supply chain environment, focusing on building inventory buffers to support future growth opportunities [22][29] Other Important Information - The company anticipates free cash flow of $220 million or more for the year, reflecting strategic increases in inventory investments [61][75] - The leverage ratio is expected to gradually decrease over time, providing more capital allocation flexibility [55][96] Q&A Session Summary Question: What drove the sales reduction to the lower end of the range? - The sales guidance was adjusted from 4% growth to 3% growth primarily due to foreign exchange headwinds, particularly with the Australian and Canadian dollars [38] Question: When do you expect improvements in the women's health and eye & ear care categories? - Management did not provide specific timelines but acknowledged ongoing challenges in these categories [40] Question: Is there any pushback from retailers on pricing? - There has been no significant pushback from retailers on pricing, as they are also facing inflationary pressures [113] Question: What percentage of growth is attributed to pricing actions? - Pricing actions are expected to account for about two-thirds of the growth for the year, estimated in the $15 million to $20 million range [117] Question: How is the company addressing supply chain disruptions? - The company is focusing on building inventory buffers and adding new suppliers to mitigate supply chain challenges [28][125]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Ju ...

50 race ENSITIVE EYES Second Quarter FY 2023 Results November 3吋, 2022 RIPLE CLEAN 0 ULTIMATE Prestige Consumer HEALTHCARE Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, diluted EPS, leverage, free cash flow, and organic revenue growth; the Company's ability to execute on its brand-building strategy; ...